A phase 1/2 dose-escalation study of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute leukemias (Genzyme Corporation Protocol CLO21800205).

Trial Profile

A phase 1/2 dose-escalation study of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute leukemias (Genzyme Corporation Protocol CLO21800205).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Clofarabine; Cyclophosphamide; Etoposide
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jun 2011 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top